摘要
目的:盐酸坦索罗辛单药及与非那雄胺联合用药对不同年龄良性前列腺增生症(BPH)的疗效评价。方法:99例BPH患者分为<60岁或≥60岁两个年龄段,随机分为单用坦索罗辛组及与非那雄胺联合用药组。予以口服坦索罗辛0.2mg,qd,或同时予以非那雄胺5mg,qd po,疗程24周。治疗前后检测IPSS(国际前列腺症状评分)评分、生活质量指数(QOL)、最大尿流速(Q_(max))、残余尿量(PRV)及血清前列腺特异性抗原(PSA)。结果:各组患者治疗后,IPSS降低,Q_(max)得到明显改善,与治疗前相比差异具有统计学意义;同一年龄段单用药组和联合用药组比较,<60岁患者,治疗后IPSS与Q_(max)差异不显著,然而在≥60岁患者,联合用药组IPSS明显较低同时Q_(max)明显较高,差异显著。QOL、PRV和PSA在各组治疗前后差异均不显著。同一年龄段两组之间不良反应差异不显著。结论:坦索罗辛单药及与非那雄胺联合均能改善BPH患者病情,≥60岁患者,联合用药疗效更好,具有统计学意义。
Objective： To evaluate the different effect of tamsulosin and tamsulosin/proscar combination in the treatment of benign prostatic hyperplasia （BPH） patients with different ages. Method： 99 cases, catalyzed first into age 〈 60 and age≥60, were randomly divided into two groups, tamsulosin group and tamsulosin/proscar combination group. Patients were treated with tamsulosin 0.2mg, qd or combined with proscar 0.2mg, qd for 24 weeks. IPSS, QOL, Qmax, PRV and PSA were measured before and after the treatment. Result： After 24 weeks Jtreatment, patients in both groups had obviously lower IPSS and higher Qmax compared with that before the treatment. In the patients with age 〈 60, there was no obvious difference between tamsulosin and tamsulosin/proscar combination treatment for 24 weeks, while in the patients with age≥60, the combination treatment caused lower IPSS and higher Qmax. Such indexes as QOL, PRV, PSA and side- effects of drugs had no significant difference in both groups after the treatment. Conclusion： Both tamsulosin alone and tamsulosin/proscar combination were effective in reducing the clinical symptoms of patients with BPH. In patients with age≥ 60, the combination had better effects.
出处
《药物流行病学杂志》
CAS
2009年第5期324-326,共3页
Chinese Journal of Pharmacoepidemiology
